Novo Nordisk has announced major price cuts for its popular medications Ozempic and Wegovy in the US market. The company will reduce Ozempic's list price by 34% and implement cuts of up to 50% on US list prices for both medications. These substantial reductions represent a significant strategic move to improve accessibility and address affordability concerns for these high-demand diabetes and weight-loss treatments.
Novo Nordisk Announces Major Price Cuts for Ozempic and Wegovy in US Market
